Mumbai, Sept. 17 -- The capsules will be available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths and are bioequivalent to REVLIMID(R) capsules of Bristol-Myers Squibb Company. The product will be manufactured at Lupin's Pithampur facility in India.
Lenalidomide capsules are used to treat adult patients with multiple myeloma (in combination with dexamethasone), multiple myeloma as maintenance therapy following autologous hematopoietic stem cell transplantation (auto-HSCT), and transfusion-dependent anemia caused by low- or intermediate-1-risk myelodysplastic syndromes (MDS) with a deletion 5q abnormality, with or without additional cytogenetic abnormalities.
The RLD REVLMID(R) version of lenalidomide had estimated annual U.S. s...